Daily Digest
Daily Digest
Pomegra Newswire
Healthcare, pharma, and biotech market news: drug approvals, trial results, and the deals reshaping the sector.
Charles River Laboratories (CRL) jumped 5.7% at its September 24 Investor Day after lifting 2026 earnings guidance and projecting 5-7% annual organic revenue growth through 2030 alongside a ~24%…
Ken Langone told CNBC that Eli Lilly (LLY) could reach $2,000 in three to four years, citing a $17-18B annual R&D budget and pipeline depth well beyond GLP-1s.
Telix Pharmaceuticals (TLX) fell nearly 10% after its $1.65B acquisition of ITM Isotope Technologies Munich created a radiopharmaceutical powerhouse with $1.3B in pro forma revenue across 65+…
NVO shares slid as much as 9% after its Capital Markets Day in London, as a $23B pipeline target and patent-cliff questions hammered investor confidence in the Wegovy maker's growth story.
Xenon Pharmaceuticals shares collapsed nearly 29% after the company voluntarily paused new enrollment in its Phase 3 depression trials citing neuropsychiatric adverse events, even as it filed a…
Longeveron's laromestrocel missed its primary endpoint in 40 HLHS infants, triggering a 57% stock crash and a full strategic review as the company's cash runway narrows into year-end.
Biotech venture funding surpassed $500 million in a single week, with Solstice Oncology and Encoded Therapeutics anchoring a $75 million gene-therapy raise as institutional capital shifts away…
Elevance Health shares climbed 4.1% after the managed-care insurer proactively reaffirmed full-year 2026 EPS and benefit expense guidance, standing out as one of the session's rare defensive…
Artisan Partners is demanding a Novartis board overhaul and M&A strategy reset after three consecutive clinical failures erased roughly $30 billion in market value, with NVS stock staging a…
Pulmovant's mosliciguat becomes the first drug to meet a Phase 2 primary endpoint in pulmonary hypertension with interstitial lung disease, a disease with zero approved treatments, vaulting ROIV…
Boston Scientific (BSX) warns it will miss 2026 EPS guidance after an August 25 cyberattack halted manufacturing and global order fulfillment, the first major med-tech guidance withdrawal tied to…
Novartis's pelacarsen missed the primary endpoint in the 8,323-patient Lp(a)HORIZON trial Sept. 7, raising the unsettling question of whether lowering lipoprotein(a) prevents cardiovascular events…
Ultragenyx RARE fell 47% after GTX-102 missed every primary and secondary endpoint in the ASPIRE Phase 3 Angelman syndrome study, triggering mass downgrades.
Ultragenyx Pharmaceutical shares collapsed nearly 47% after apazunersen failed every endpoint in the Phase 3 Aspire Angelman study, erasing $1.14 billion in market value and forcing a strategic…
Novartis's remibrutinib cleared every Phase 3 hurdle in relapsing MS, sending NVS up 4% and intensifying the battle for a $40 billion disease market.
Johnson & Johnson shares hit an all-time high of $276.50 as the most aggressive institutional defensive rotation of 2026 floods capital into J&J's diversified pharma-medtech franchise and 54-year…
Pfizer (PFE) climbs to its highest close since October 2024 while Solventum posts a 52-week record as capital rotates into defensive dividend-paying healthcare.
Veeva Systems sustains a post-earnings rally exceeding 15% into September after a beat-and-raise quarter confirms Vault CRM's structural displacement of Salesforce Health Cloud in life sciences.
Medtronic Q1 FY2027 earnings due Monday, with analysts forecasting $1.38 EPS and $8.54 billion in revenue while investors scrutinize its AI-guided surgical robotics and GLP-1 platform progress.
McKesson (MCK) will pay $2.25 billion for Precision Medicine Group, buying a global oncology CRO from Blackstone in the largest healthcare services deal of the week.
Medline Industries surges as much as 40% on its first trading day after raising $5.26 billion in the year's largest IPO, a 10-times-oversubscribed offering that sets a new record for PE-backed…
Veeva Systems jumped as much as 19% after reporting Q2 FY2027 revenue and profit that surpassed Wall Street expectations, driven by Vault CRM wins at Biogen and Regeneron as the company displaced…
Boston Scientific shares tumbled sharply after a simultaneous cyberattack and product recall disrupted global operations, with analysts warning recovery could take weeks.
Barclays declares the biotech M&A freeze definitively over on CNBC as 2026 pharma dealmaking crosses $134B across 33 deals, led by AbbVie's $10.9B Apogee acquisition and Roche's Hanmi obesity bet.
Merck surged 12.6% on August 19 as a Phase 3 mRNA melanoma vaccine with Moderna cleared key endpoints, marking the first neoantigen therapy to succeed at that stage and easing fears about…
Moderna shares posted a historic single-session gain after intismeran cleared its Phase 3 melanoma primary endpoint, triggering an $8 billion short squeeze and redefining the outlook for biotech…
Capricor Therapeutics stock more than doubled in a single session after landmark Phase 3 trial results for its Duchenne muscular dystrophy therapy cleared the field's highest evidentiary bar, with…
Moderna's mFLUSIVA becomes the first FDA-approved mRNA flu vaccine, cleared Aug. 5, 2026 for adults 50 and older, lifting MRNA shares nearly 4% to $56.99.
Replimune shares vaulted more than 127% after an FDA advisory committee voted 10-3 to endorse the efficacy of its combination melanoma therapy, adding nearly $600 million in market value ahead of…
Abivax closes a $920 million equity offering to independently commercialize obefazimod in the U.S. for ulcerative colitis, bypassing a Big Pharma deal and targeting an NDA filing in Q4 2026.
Healthcare investing runs on binary events. A drug trial readout or an FDA approval decision can double a biotech or cut it in half overnight, because a small company's whole valuation may rest on one molecule. The desk covers those catalysts - trial results, approvals, and the label details that decide a drug's market - alongside the steadier earnings of large pharma, insurers, and device makers.
The sector is also the classic defensive play: people need medicine in every economy, so healthcare earnings hold up when cyclical sectors roll over. Coverage links each story to the wiki entries on the science terms and the sector mechanics, so a headline about a Phase 3 miss explains itself.
Small biotech valuations often rest on one or two drug candidates, so trial results and FDA decisions can reprice the whole company overnight.
Pomegra